Merck & Co. Inc. (MRK) Q2 2026 (USD) Adj. EPS -0.13 (exp. -0.27), Revenue 16.6bln (exp. 16.37bln), Current FY EPS 2.66-2.76 (exp. 2.76), Current FY Rev. 66.3-67.3bln (exp. 66.83bln)

• Total Worldwide Sales USD 16.6bln (5% Growth; 4% Growth ex-FX)
• KEYTRUDA/KEYTRUDA QLEX1 Sales USD 8.4bln (5% Growth; 4% Growth ex-FX); Includes KEYTRUDA QLEX Sales of USD 463mln
• WINREVAIR Sales USD 588mln (75% Growth; 75% Growth ex-FX)
• Animal Health Sales USD 1.8bln (8% Growth; 5% Growth ex-FX)

The print beats on both lines while full-year EPS guidance straddles the consensus at its top end and revenue guidance brackets it, a pattern that in past large-cap pharma quarters has tended to produce a muted or faded initial reaction rather than a sustained re-rating, since the market reads guidance held rather than raised as conservatism, not weakness. The structural story is the established one: Keytruda remains the dominant revenue engine, and single-digit growth in the franchise has historically shifted attention toward the longer-dated loss-of-exclusivity question, which has tended to cap multiple expansion regardless of quarterly beats. The offset is the newer growth assets, where the pulmonary hypertension launch continues to compound at a rate the street has tended to reward when it offsets deceleration in the core oncology line. The distinction worth drawing is between the EPS beat driven by the quarter itself and the unchanged-to-slightly-soft full-year frame: the former is backward-looking, the latter is what drives estimate revisions. Worth watching is the call commentary on Keytruda trajectory, pipeline read-throughs, and any FX assumption embedded in guidance, given the ex-FX growth gap. The ticker collision with the German namesake is a recurring source of misrouted flows in early trade.